DelveInsight forecasts the congestive heart failure market to expand at an 8% CAGR through 2036, signaling rising therapeutic and device demand amid an aging population
Executive summary: DelveInsight published a market forecast projecting the global congestive heart failure (CHF) market to grow at a compound annual growth rate of 8% from 2026 to 2036. The projection reflects increasing prevalence of cardiovascular diseases, an aging global population, and greater awareness of early diagnosis, highlighting expanding opportunities for drug developers, device manufacturers, and healthcare providers.
Who is involved: Key actors include DelveInsight (research firm), pharmaceutical and medical device companies pursuing CHF therapies, regulators overseeing drug approvals, and the aging patient population driving demand.
Likely next: Stakeholders are expected to advance late‑stage clinical trials of novel CHF agents, seek regulatory approvals for new devices, and adapt reimbursement policies to accommodate rising treatment volumes.
DelveInsight’s latest report projects the global congestive heart failure (CHF) market to grow at a compound annual growth rate of 8% from 2026 to 2036, driven by increasing cardiovascular disease prevalence, an aging population, and greater awareness of early diagnosis and disease management. The forecast underscores a expanding addressable market for pharmaceutical therapies, ventricular assist devices, and remote monitoring solutions, which could stimulate higher R&D spending and broader reimbursement discussions. While the outlook is positive for industry players, it also highlights growing healthcare cost pressures that payers and governments may need to address.
Timeline
- — Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight (PR Newswire)
Analysis — what this means
Sectors affected
- Cardiovascular therapeutics
- Ventricular assist device manufacturers
- Remote patient monitoring solutions
Historical parallels
- FDA approval of sacubitril/valsartan (Entresto) for heart failure in July 2016
- EMA approval of dapagliflozin for heart failure in 2021
Key entities
Sources
Open the full interactive case file on Beyond →